Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT03493256
Other study ID # KB 776/2017
Secondary ID
Status Completed
Phase
First received
Last updated
Start date April 1, 2018
Est. completion date March 1, 2019

Study information

Verified date February 2020
Source Collegium Medicum w Bydgoszczy
Contact n/a
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

In this single center prospective cohort study a total of 100 patients scheduled for elective off-pump CABG will be recruited. They will be allocated to one study and one control group according to the presence or absence of postoperative type 2 neurological complications. The two groups will be compared in terms of serum concentrations of glial fibrillary acidic protein (GFAP), neuroserpin (NSP), phosphorylated axonal neurofilament subunit H (pNfH) and visinin-like protein 1 (VILIP-1) at the time of skin incision and closure as well as 24 hours and 7 days following surgery. Diagnostic performance of these markers for predicting type 2 neurological complications of off-pump CABG will be assessed.


Recruitment information / eligibility

Status Completed
Enrollment 100
Est. completion date March 1, 2019
Est. primary completion date March 1, 2019
Accepts healthy volunteers
Gender All
Age group N/A and older
Eligibility Inclusion Criteria:

- patients scheduled for elective off-pump Coronary Artery Bypass Grafting (CABG)

Exclusion Criteria:

- neurological or psychiatric disorders

- alcohol or drug abuse

- preoperative left ventricular ejection fraction of less than 30%

- extracranial carotid artery stenosis of more than 70%

- scoring below age- and education-adjusted cut-off values in Mini-Mental State Examination (MMSE)

- scoring over seven points on the subscales of the Hospital Anxiety and Depression Scale (HADS)

Study Design


Related Conditions & MeSH terms

  • Neurological Complication of Procedure (Disorder)

Intervention

Other:
exposure to type 2 neurological complications
exposure to postoperative cognitive dysfunction (POCD) or postoperative delirium (POD), or both concurrently.

Locations

Country Name City State
Poland Department of Cardiac Surgery, Dr Antoni Jurasz Memorial University Hospital Bydgoszcz Kujawsko-Pomorskie

Sponsors (1)

Lead Sponsor Collaborator
Collegium Medicum w Bydgoszczy

Country where clinical trial is conducted

Poland, 

Outcome

Type Measure Description Time frame Safety issue
Primary Assessment of serum GFAP concentration (ng/ml) changes. Comparison of patients with and without type 2 neurological complications in respect to changes from baseline concentration of glial fibrillary acidic protein (GFAP). GFAP concentrations will be measured preoperatively (at the time of initial skin incision), at the completion of surgery (at the time of skin closure) as well as 24 hours and 7 days following off-pump Coronary Artery Bypass Grafting (CABG).
Primary Assessment of serum NSP concentration (ng/ml) changes. Comparison of patients with and without type 2 neurological complications in respect to changes from baseline concentration of neuroserpin (NSP). NSP concentrations will be measured preoperatively (at the time of initial skin incision), at the completion of surgery (at the time of skin closure) as well as 24 hours and 7 days following off-pump Coronary Artery Bypass Grafting (CABG).
Primary Assessment of serum pNfH concentration (ng/ml) changes. Comparison of patients with and without type 2 neurological complications in respect to changes from baseline concentration of neuroserpin phosphorylated axonal neurofilament subunit H (pNfH). pNfH concentrations will be measured preoperatively (at the time of initial skin incision), at the completion of surgery (at the time of skin closure) as well as 24 hours and 7 days following off-pump Coronary Artery Bypass Grafting (CABG).
Primary Assessment of serum VILIP-1 concentration (ng/ml) changes. Comparison of patients with and without type 2 neurological complications in respect to changes from baseline concentration of visinin-like protein 1 (VILIP-1). VILIP-1 concentrations will be measured preoperatively (at the time of initial skin incision), at the completion of surgery (at the time of skin closure) as well as 24 hours and 7 days following off-pump Coronary Artery Bypass Grafting (CABG).